These findings suggest that the loss of cardiac PCs is linked to cardiomyopathy, and that SGLT2 inhibitors help mitigate PC loss while improving cardiomyopathy in individuals with type 2 diabetes [148]. Here, SLC5A2 is linked to cardiomyopathy.